

Michiel Coppens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/905373/publications.pdf>

Version: 2024-02-01

59
papers

3,562
citations

448610

19
h-index

156644

58
g-index

62
all docs

62
docs citations

62
times ranked

6397
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1995-2002.	1.9	1,227
2	Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. <i>Blood</i> , 2014, 124, 1968-1975.	0.6	662
3	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , 2019, 179, 1469.	2.6	283
4	Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. <i>European Journal of Heart Failure</i> , 2017, 19, 1427-1443.	2.9	236
5	Gene therapy with adeno-associated virus vector 5- μ human factor IX in adults with hemophilia B. <i>Blood</i> , 2018, 131, 1022-1031.	0.6	236
6	A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. <i>Blood</i> , 2006, 108, 2604-2607.	0.6	65
7	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2415-2424.	1.8	62
8	Sex, thrombosis and inherited thrombophilia. <i>Blood Reviews</i> , 2014, 28, 123-133.	2.8	56
9	<i>In vivo</i> reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. <i>British Journal of Haematology</i> , 2016, 172, 255-261.	1.2	48
10	Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 645-653.	1.9	48
11	Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 118-129.	1.0	47
12	Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B. <i>Blood</i> , 2019, 134, 2059-2059.	0.6	42
13	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , 2020, 4, 3520-3527.	2.5	38
14	Delivery of AAV-based gene therapy through haemophilia centres: A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. <i>Haemophilia</i> , 2021, 27, 967-973.	1.0	29
15	Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. <i>Patient</i> , 2020, 13, 201-210.	1.1	28
16	Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Advances</i> , 2020, 4, 6291-6297.	2.5	28
17	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. <i>Atherosclerosis</i> , 2022, 341, 43-49.	0.4	28
18	Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. <i>Blood</i> , 2021, 138, 2853-2873.	0.6	23

#	ARTICLE	IF	CITATIONS
19	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.	1.8	23
20	Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. <i>American Journal of Hematology</i> , 2021, 96, 51-59.	2.0	21
21	Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2394-2406.	1.9	21
22	Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent. <i>Canadian Journal of Cardiology</i> , 2014, 30, 381-384.	0.8	20
23	Effects of a hospital-wide introduction of a massive transfusion protocol on blood product ratio and blood product waste. <i>Journal of Emergencies, Trauma and Shock</i> , 2015, 8, 199.	0.3	18
24	Joint status of patients with nonsevere hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1126-1137.	1.9	17
25	Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2687-2701.	1.9	16
26	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous thromboembolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018, 16, 9.	0.9	15
27	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. <i>Haemophilia</i> , 2021, 27, 876-885.	1.0	14
28	Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. <i>Thrombosis Research</i> , 2017, 160, 76-82.	0.8	13
29	AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years. <i>Blood</i> , 2020, 136, 26-26.	0.6	13
30	Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. <i>Blood Transfusion</i> , 2017, 15, 369-377.	0.3	13
31	Coagulation factor XIII-A subunit and activation peptide levels in individuals with established symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2017, 159, 96-99.	0.8	11
32	First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. <i>Blood</i> , 2020, 136, LBA-6-LBA-6.	0.6	11
33	Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1158-1165.	1.9	11
34	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. <i>Haemophilia</i> , 2022, 28, .	1.0	10
35	The bleeding phenotype in people with nonsevere hemophilia. <i>Blood Advances</i> , 2022, 6, 4256-4265.	2.5	10
36	Inherited Thrombophilias. <i>Obstetrics and Gynecology Clinics of North America</i> , 2006, 33, 357-374.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. <i>American Journal of Hematology</i> , 2020, 95, 1142-1147.	2.0	9
38	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. <i>Lancet Haematology</i> , 2021, 8, e492-e502.	2.2	9
39	Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2171-2181.	1.9	8
40	Generic PROMIS item banks in adults with hemophilia for patient-reported outcome assessment: Feasibility, measurement properties, and relevance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12621.	1.0	8
41	Recognition and Management of Hemostatic Disorders in Critically Ill Patients Needing to Undergo an Invasive Procedure. <i>Transfusion Medicine Reviews</i> , 2017, 31, 223-229.	0.9	7
42	Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. <i>BMJ Open</i> , 2019, 9, e022719.	0.8	7
43	Natural Course of the Subsequent Pregnancy after a Single Loss in Women with and without the Factor V Leiden or Prothrombin 20210A Mutations. <i>Blood</i> , 2006, 108, 275-275.	0.6	7
44	Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1376-1384.	1.9	7
45	Optimal trough levels in haemophilia B: Raising expectations. <i>Haemophilia</i> , 2020, 26, e334-e336.	1.0	6
46	Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline. <i>Clinical Nutrition</i> , 2016, 35, 1579-1580.	2.3	5
47	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020, 82, 48-55.	1.0	5
48	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , 2020, 196, 297-304.	0.8	5
49	Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B. <i>Blood</i> , 2016, 128, 2314-2314.	0.6	5
50	First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years. <i>Blood</i> , 2021, 138, 3971-3971.	0.6	5
51	Professional functioning of young adults with congenital coagulation disorders in the Netherlands. <i>Haemophilia</i> , 2019, 25, e138-e145.	1.0	4
52	Safety of prothrombin complex concentrate in healthy subjects. <i>British Journal of Haematology</i> , 2017, 176, 664-666.	1.2	3
53	Illness cognitions associated with health-related quality of life in young adult men with haemophilia. <i>Haemophilia</i> , 2020, 26, 793-799.	1.0	2
54	Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12748.	1.0	2

#	ARTICLE	IF	CITATIONS
55	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. Blood, 2019, 134, 711-711.	0.6	1
56	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). TH Open, 2022, 06, e60-e69.	0.7	1
57	Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thrombosis Research, 2020, 196, 404-409.	0.8	0
58	Current Practice of Testing for Hereditary Thrombophilia in the Netherlands.. Blood, 2006, 108, 3288-3288.	0.6	0
59	“Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism” Reply. Journal of Thrombosis and Haemostasis, 2022, 20, 1748-1749.	1.9	0